CD44, which is differentially expressed in highly metastatic versus low metastatic breast cancer cells, was shown to mediate the transfer of ezrin as cargo in EVs that also transfer MDR Pgp1 to low metastatic cells and confer therapeutic resistance [61]. This evidence concerns the gene CD44 and breast carcinoma.